Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134517 | 0.88 | PPARA (0.40) | PPARAPLA2G4BHPGDALDH1A1PPARG | |
| SCHEMBL7073655 | 0.87 | CHRNB2 (0.42) | — | |
| SCHEMBL7076018 | 0.84 | PKM (0.44) | TDP1PPARAPLA2G4BHDAC1HDAC2 | |
| SCHEMBL7077804 | 0.79 | HCRTR2 (0.40) | — | |
| SCHEMBL7080512 | 0.73 | PPARA (0.44) | PPARAPLA2G4BL3MBTL1ALDH1A1PPARG | |
| SCHEMBL7077468 | 0.72 | CHRNB2 (0.46) | — | |
| SCHEMBL6819996 | 0.72 | LTA4H (0.45) | TDP1PPARAHPGDL3MBTL1KDM4E | |
| SCHEMBL7759139 | 0.72 | MAPK1 (0.45) | TDP1PPARAHPGDALDH1A1RECQL | |
| SCHEMBL7759143 | 0.72 | MAPK1 (0.45) | TDP1PPARAHPGDALDH1A1RECQL | |
| SCHEMBL6945866 | 0.72 | MAPK1 (0.45) | TDP1PPARAHPGDALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | TDP1 2654/4885PPARA 761/4885PLA2G4B 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.